Remix Therapeutics
- Founded: 2019
- Location: Cambridge, MA
- Employee range: 50 - 200
- Clinical stage: RD
- Therapy area: Oncology
- Drug types: ONC, NEU, GEN
- Lead product: Undisclosed
- Product link: https://www.remixtx.com/science/
- Funding: $70M B May 2022; $81M A Dec 2020
- Investors: Surveyor, Foresite Capital, Atlas Venture, The Column Group, Arch Venture Partners, Alexandria Venture Investments, Casdin Capital
remixtx.com linkedin.com job board
Short description:
Small molecule therapies designed to reprogram RNA processing
Drug notes:
Additional undisclosed programs RD CNS diseases, genetic disorders, undisclosed
Long description:
Remix Therapeutics is developing small molecule therapeutics to alter the expression of mRNA and proteins driving disease. RNA processing is a tightly regulated process that impacts the abundance of proteins synthesized. Using their REMaster drug discovery platform, Remix is identifying druggable target sites and active chemical matter to advance novel therapies that can alter RNA expression and restore functional levels. The proprietary platform combines data science and bioinformatics to identify modifiable sites with multiplexed high-throughput screening technologies that uses their chemical library enriched for compounds that can interact with RNA processing machinery. Remix is currently building a pipeline of RNA processing modulators across oncology and neurodegeneration.
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com